MOCA II and REVITALISE Trials Progressing
CorFlow Therapeutics AG has made significant strides by completing Phase 1 and initiating Phase 2 of its MOCA II pivotal trial. approval has been received to launch the REVITALISE RCT trial in Europe, signalling major advancements in their clinical programme focused on heart attack treatment.
During Phase 1 of the MOCA II trial, 19 STEMI patients were enrolled across five US and three European sites to diagnose microvascular obstruction (MVO) using the PCoFI measurement, comparing it to cardiac MRI. Key safety and performance goals were successfully met.
At Cardiocentro Ticino Institute in Lugano, Switzerland, Professor Marco Valgimigli enrolled the first patients for Phase 2 of MOCA II. He expressed excitement over the new technology, which aims to enhance decision-making in cath labs and improve STEMI patient management.
MOCA II’s primary goal is to validate the threshold value of the PCoFI measurement during primary angioplasty when diagnosing MVO, compared to cardiac MRI. With Phase 1 completed, Phase 2 will extend to more clinical trial sites in the US and Europe.
REVITALISE Trial Set for Launch
The REVITALISE trial is ready to commence in the UK, with France, the Netherlands, and Spain following soon. This trial will evaluate the efficacy of the CorFlow Continuous Flow Infusion System in treating MVO during primary angioplasty for STEMI patients. Plans are in place to enroll over 250 patients, with initial results anticipated in 2027.
Paul Mead, CEO of CorFlow, highlighted partnerships with leading research institutions in the US and Europe. Nearly 50 top-tier hospitals will participate in these studies, advancing interventional cardiology.
CorFlow has strengthened its clinical leadership by appointing Dr. Rick Kuntz as an Observer and senior scientific advisor on their Board of Directors, and Dr. Pedro Eerdmans as Vice President Clinical. Both bring extensive experience in medical research and development.
The randomized REVITALISE trial will soon begin enrollment in the UK, with France, the Netherlands, and Spain to follow. Its adaptive platform approach allows for testing additional drug candidates through subsequent trial arms.
The REVITALISE trial will prospectively test the effectiveness of the CorFlow Continuous Flow Infusion System (CoFI System) in delivering therapeutic agents for MVO treatment. Data read-outs are expected through 2028.
Last updated: 1 May 2026, 12:19 am
